TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Overall rates of occurrence and severity of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: satisfaction with the simulation learning experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FeNa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CCr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Numbers of CD3+, CD4+, CD8+, CD25+, and NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Preventive referrals and health behavior changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rates of lessons
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effect sizes for social phobia measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of procedures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prolactin level increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak postprandial blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of developing dyspepsia severe enough to necessitate discontinuation of NSAIDs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of medial rotation of the testis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Time for successful treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-menstruation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tramadol requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: poor liver function on postoperative day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extracellular volume to intracellular volume ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tibial rotation during dynamic activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage serum leptin decline from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recall rate for congenital hypothyroidism screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: in-hospital survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of self-initiated questions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Thyroid ¹³¹I uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: lower prevalence of substance misuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of liver cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: probability of severe event occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: probability of clinical event occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: clinical time required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of clinical sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of ordering antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of ordering rapid streptococcal tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality due to neutropenic sepsis
Endpoint domain: Mortality/survival
Primary endpoint: Maternal, family, and child indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of exogenous hormones in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnea occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to achieve anesthetic concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of bronchospasm
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of homogeneity of grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of inflammatory events (facial oedema)
Endpoint domain: Adverse events/effects
Primary endpoint: Paco2 variability after transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: residence in long-term care
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Micronucleus (MN) count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EABR threshold stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Slope of the EABR growth function stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Behavioral measures of threshold and dynamic range stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: medication self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerance of G17DT
Endpoint domain: Adverse events/effects
Primary endpoint: Cure rate of infantile colic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of patients who could benefit from brief alcohol interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Birth Weight (LBW) infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placental malaria prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maternal anemia at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nicotine dependence reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max,ss) with revaprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(τ,ss) with revaprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of diarrhea of Grade 2 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Sd-LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Reduction of keratometric cylinder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cycle 1 Cmax for T-DM1 conjugate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cycle 1 Ctrough for T-DM1 conjugate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf for T-DM1 conjugate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early-stage lesion remineralisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: advanced lesion demineralisation prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sPGA success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset time to 95% depression of first twitch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total recovery time (TOF ratio 0.9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical duration until first twitch has recovered to 25%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: lower esophageal sphincter pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: postoperative dysphagia rate
Endpoint domain: Adverse events/effects
Primary endpoint: Digit span
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to RA development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial IGFBP‐1 reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Bioactive IGF‐I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Success rate of DCR surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FA value in the genu of the corpus callosum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FA value in the centrum semiovale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FA value in the frontal white matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: walking speed and endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: force production through the affected leg during sit‐to‐stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of repetitions of the step test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slower eGFR decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean duration of fever after administration (DFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with bleaching results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Esthetic result of teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of panic attacks
Endpoint domain: Adverse events/effects
Primary endpoint: maximal percent decrease in FEV1 after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean time to recovery after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response rate (complete remission/CR with incomplete count recovery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of saphenous nerve block until first opioid request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption during the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condom use with risky context partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time elapsed before recovery of 90% of neuromuscular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relieving rate of dysmenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Uterine volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Levels of LH, FSH and E(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: psychological symptoms of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum vitamin D level at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean scores of symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of pain-free patients 30 minutes after the procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in waist circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycated hemoglobin (Hb A(1c))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of life (EQ-5D Index score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevention of PCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall appearance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean blood loss in the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHO performance status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction in studies
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in dyspareunia VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UUI (Urgency Urinary Incontinence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FPG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunization coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD-behavior improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gain in language function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: gain in visuospatial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: gain in verbal episodic memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Non-compliance probability
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation due to toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: ACh-stimulated forearm blood flow (FBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mucociliary Clearance (MCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean hematocrit levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean nighttime diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cure probability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in CFUs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS motor function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year mortality after discharge
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of apoptosis in CD8(+) lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of infectious complications during the postoperative course
Endpoint domain: Adverse events/effects
Primary endpoint: hair scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline TSH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: fT3 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: fT4 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: oocyte yield variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Completion of the FAST parent programme
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CE transfer rates from HDL3 to apoB-lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capacity of HDL2 particles to mediate free cholesterol efflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selective hepatic uptake of CE from HDL particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PHQ-9 responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CO(2) reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCA MFV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heroin abstinence symptoms disappearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Course of the disease duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver fibrosis reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: functional results
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total number of hospital readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Length of stay during all-cause readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: risk of re-treatment
Endpoint domain: Mortality/survival
Primary endpoint: mean direct cost of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean total cost for the HE‐TUMT and TURP group
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: total hair density (hair/cm2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: meaningful hair density (non‐vellus hair/cm2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial increase in lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: persistent postprandial hyperinsulinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: lipoperoxidation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mineralization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Increase in hematocrit levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recurrence rate after treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Incident sexually transmitted infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Unprotected sex with outside partners
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: BAFMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endothelin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of positive skin reactions to cockroaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean for total IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hospitalizations for HF
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: days hospitalized related to primary diagnosis of HF
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: short-term efficacy of appetite-suppressant drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCr tests ordered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pigment Concentration (PC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color Change (ΔE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) for R-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) for R-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) for S-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) for S-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of positive ACLA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of total line infections
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of gram-positive line infections
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of gram-negative line infections
Endpoint domain: Adverse events/effects
Primary endpoint: Complete absence of heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: WB BMC Z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior chamber angle (ACA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle opening distance (AOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean real central anterior chamber depth (rACD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSA at the tunnel inlet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of NCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of NCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in photoaging scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ACR50 achievement at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes